TWIST BIOSCIENCE CORPORATION

Twist Bioscience Corporation specializes in high-throughput DNA synthesis and custom oligonucleotide library development for biomedical research and diagnostics. Their core capabilities center on synthetic biology platforms that enable precise gene assembly, saturation mutagenesis, targeted capture panels, and next-generation sequencing library preparation. The company delivers proprietary DNA synthesis technologies to support complex applications such as monoclonal antibody engineering, gene expression profiling via MPRA, and blood-based cancer diagnostics, including detection of viral pathogens like HHV8 in HIV patient plasma. Their technical differentiation lies in scalable, silicon-based DNA manufacturing that ensures high fidelity, low error rates, and rapid turnaround for research-grade nucleic acid constructs, positioning them as a critical enabler for precision genomics and functional genomics initiatives. Twist Bioscience primarily supports the Department of Health and Human Services, providing tailored molecular reagents and synthesis services for NIH institutes and other HHS components engaged in infectious disease, oncology, and functional genomics research. They also deliver specialized biological materials to the Department of Veterans Affairs, including sample preparation tools for FFPE tissue analysis and humanized antibody development for translational studies. Their engagement with these agencies reflects a consistent pattern of supporting discovery-phase research requiring customized DNA constructs and validated reagents. The contractor’s primary focus is in Research and Development in Biotechnology (NAICS 541714), where they serve as a niche supplier of synthetic DNA for academic and government labs conducting gene editing, target validation, and diagnostic assay development. Additional work in testing laboratories and medical instrument manufacturing underscores their role in end-to-end molecular diagnostics workflows. Twist Bioscience is a private corporation headquartered in San Francisco, California, with no federal certifications on record. Their market positioning is defined by proprietary DNA synthesis technology that bridges academic research and government-funded biomedical innovation, serving as an essential enabler for next-generation sequencing and synthetic biology programs across the federal research ecosystem.